Centre allows commercial launch of ‘Feluda’, first CRISPR COVID-19 test
NEW DELHI: The Drugs Controller General of India has permitted the business launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) mentioned on Saturday.
This test makes use of an indigenously developed, cutting-edge CRISPR expertise for detection of the genomic sequence of SARS-CoV-2 virus, CSIR mentioned in a press release.
The Tata CRISPR test achieves accuracy ranges of conventional RT-PCR checks with faster turnaround time, inexpensive tools and higher ease of use. CRISPR is a genome enhancing expertise to diagnose ailments. The expertise has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology).
“The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from DCGI for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting novel coronavirus,” the assertion mentioned.
The Tata CRISPR test is the world’s first diagnostic test to deploy a specifically tailored Cas9 protein to efficiently detect the virus inflicting COVID-19, it mentioned.
Moreover, CRISPR is a futuristic expertise that may also be configured for detection of a number of different pathogens sooner or later.
“The Tata Group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up COVID-19 testing quickly and economically, with a ‘Made in India’ product that is safe, reliable, affordable and accessible,” the assertion added.
Commenting on the event, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd mentioned, “The approval for the Tata CRISPR test for COVID-19 will enhance the nation’s efforts in preventing the worldwide pandemic.
“The commercialisation of Tata CRISPR test reflects the tremendous R&D talent in the country which can collaborate to transform India’s contributions to the global healthcare and scientific research world,” he mentioned.
Anurag Agrawal, director, CSIR-IGIB, mentioned the work began by CSIR underneath the sickle cell mission for genome diagnostics and therapeutics led to new data that may very well be harnessed to shortly develop new diagnostic test for SARS-CoV-2.
He emphasised that this reveals the interconnectedness of scientific data and expertise and the innovation of the younger analysis group led by Debojyoti Chakraborty and Souvik Maiti.
$(function() { return $("[data-sticky_column]").stick_in_parent({ parent: "[data-sticky_parent]" }); });
reset_scroll = function() { var scroller; scroller = $("body,html"); scroller.stop(true); if ($(window).scrollTop() !== 0) { scroller.animate({ scrollTop: 0 }, "fast"); } return scroller; };
window.scroll_it = function() { var max; max = $(document).height() - $(window).height(); return reset_scroll().animate({ scrollTop: max }, max * 3).delay(100).animate({ scrollTop: 0 }, max * 3); };
window.scroll_it_wobble = function() { var max, third; max = $(document).height() - $(window).height(); third = Math.floor(max / 3); return reset_scroll().animate({ scrollTop: third * 2 }, max * 3).delay(100).animate({ scrollTop: third }, max * 3).delay(100).animate({ scrollTop: max }, max * 3).delay(100).animate({ scrollTop: 0 }, max * 3); };
$(window).on("resize", (function(_this) { return function(e) { return $(document.body).trigger("sticky_kit:recalc"); }; })(this));
}).call(this);
} on_load_google_ad(); function sendAdserverRequest() { try { if (pbjs && pbjs.adserverRequestSent) return; googletag.cmd.push(function() { googletag.pubads().refresh(); }); } catch (e) {
googletag.cmd.push(function() { googletag.pubads().refresh(); }); } } setTimeout(function() { sendAdserverRequest(); }, 5000);
function on_load_fb_twitter_widgets(){ (function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.9"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
window.twttr = (function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0], t = window.twttr || {}; if (d.getElementById(id)) return t; js = d.createElement(s); js.id = id; js.src = "https://platform.twitter.com/widgets.js"; fjs.parentNode.insertBefore(js, fjs); t._e = []; t.ready = function(f) {
t._e.push(f); }; return t; }(document, "script", "twitter-wjs")); }
//setTimeout(function() { on_load_google_ad(); }, 5000); setTimeout(function() { on_load_fb_twitter_widgets(); }, 5000);
Source